TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 1-year incidence of Bleeding Academic Research Consortium ≥ 2 bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: respiratory complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean percentage improvement in overall TRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in function and disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of HOMA-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Depressive disorder prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision-specific disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete ulcer healing at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time duration of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exertion
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pupae per person index (PPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breteau index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quantity of life
Endpoint domain: Mortality/survival
Primary endpoint: Median peak CK‐MB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak quantitative cardiac troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time interval from food challenge to peak SMA flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphovascular invasion (LVi) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportions of grade 3 carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: aerobic fitness (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: auditory attention abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: registration intentions
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: registration attitudes
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Mean percent change in performance for CBC monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in performance for creatinine monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent change in performance for use of cytoprotective agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of RSFC in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Uptake of modern contraceptive methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients completing the 12-month intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of ACR50 responding patients after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: MSCopilot performance compared to MSFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECOG performance status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum Prostaglandin E2 (PGE2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: net clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the standardized patient case
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of inpatient stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: sustained deep remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low disease activity (LDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual ratio of markers in the small intestine at POD 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Excretion rate of markers at POD 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Residual ratio in the small intestine at POD 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: unadjusted mortality
Endpoint domain: Mortality/survival
Primary endpoint: 5-year tooth survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Viscoelastic properties of knee compartments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emesis free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of remineralisation of early enamel lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acid resistance of enamel after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profiles of olmesartan medoxomil and hydrochlorothiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative estimated blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: need for oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: higher hematocrit levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of presence in caregiving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients reaching composite efficacy end-points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximal intimal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of vasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Complete absence of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate decisional self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Health care satisfaction at discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disability days at 1-year follow-up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Methacetin demethylation capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ketoisocaproate decarboxylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late systolic shoulder response reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic systolic pressure response reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fractional exhaled nitric oxide (FE(NO)) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Driving pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chest wall elastance (Ecw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung elastance (EL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Processing speed improvements on UFOV scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood to stop breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Likelihood to introduce formula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of ICU-AW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin requirements to achieve glycemic goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: patient-rated total nasal score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectacle adherence ≥80% of waking hours
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cytokine levels (IL-1beta, IL-4, IL-8, IL-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Four-week continuous abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until the next cessation attempt
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Extent of smoking reduction (measured by urinary cotinine concentrations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in platelet and leukocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerability of RAD
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of chest compression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar spine bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of femoral neck bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Detection of THC in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of AVMs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sensitivity of MRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Oral bioavailability of curcumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: index of vitality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tolerability of the vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Relevance of learning content
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance of e-learning method
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (QOL) in patients with TMDs
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Need for dilatations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Esophagitis healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ΔE color change measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychosocial impact
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: esthetic self-perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in sCOMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in knee flexion and hip rotation ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pro-inflammatory cytokine IL-1α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PAC-QOL overall score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction subscale score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Well-tolerated (no serious adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Protection against diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wind-up ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain to the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluoroscopic time needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of Le (a-b+) blood group phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: detection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute infarct volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of total infarct volume over left ventricle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decline of urinary total NNN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: death, reinfarction, or heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Width of peri-implant keratinized gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flow-mediated dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: soluble intercellular adhesion molecule (sICAM‐1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: interleukin (IL)‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Child disordered behavior (ECBI Intensity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child disordered behavior (ECBI Problem subscale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent competencies and well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physician's global assessment of psoriasis 'clear' or 'almost clear'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis area and severity index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: student break frequency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvements in pre‐dose trough FEV1 and post‐dose 1‐h FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Castrate levels achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PSA levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDRS(17) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of unintended extension
Endpoint domain: Adverse events/effects
Primary endpoint: blood loss of >1500 mL
Endpoint domain: Adverse events/effects
Primary endpoint: self assessed quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Myocardial Infarction (MI) by 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistent ketonuria rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea visual numerical rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well-being scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain on activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of the overdenture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthesis stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients abstinent at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of successful treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Predictive accuracy for nondisabled 3-month outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of left ventricular end-diastolic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum high-density lipoprotein cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of IRLS score under treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe hypotension episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery room time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maintenance of weekly MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in BMI z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CSF p-tau181 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of confirmed/severe hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: total cost for thyroidectomy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ziprasidone exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean NHP volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean portal vein diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean spleen volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Renal status grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean levels of serum creatinine, blood urea, and serum cystatin C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PPARG expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean testing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in POBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of octreotide antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of morphine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum bile acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNR lumen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in wound diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of paresthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of uneven sensory levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of intravascular placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrathoracic blood volume index (ITBVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 100-m performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-HDL cholesterol change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mortality of infected mice
Endpoint domain: Mortality/survival
Primary endpoint: Body weight of infected mice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological changes of small intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intra-subject variability of FBF ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of unilateral FBF measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-subject variability of FVR ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemia time (IT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid-femoral Pulse Wave Velocity (cfPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of grade 3/4 neutropenia and thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe gastrointestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: ipsilateral recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: miscarriage rate up to 20 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: fibronectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization cost savings
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean peak oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes